Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + topotecan + estramustine
- Development stage
- Unknown
- Lead developer
- Fox Chase Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
paclitaxel + topotecan + estramustine is a combination chemotherapy regimen investigated by the Fox Chase Cancer Center for the treatment of metastatic hormone-refractory prostate cancer (mHRPC). The regimen utilizes three agents with distinct but complementary mechanisms: paclitaxel, a taxane that stabilizes microtubules to induce mitotic arrest; topotecan, a camptothecin analog that inhibits DNA topoisomerase I to cause lethal DNA damage; and estramustine phosphate, a conjugate of estradiol and nitrogen mustard that disrupts microtubule dynamics by binding to microtubule-associated proteins. This multi-targeted approach was evaluated in Phase II clinical trials to improve outcomes in patients whose prostate cancer had become resistant to standard hormonal therapies.
- Other names
- paclitaxel, topotecan, and estramustine combination
02
Targets
TOP1 (DNA Topoisomerase I)ER (Estrogen receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + topotecan + estramustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + topotecan + estramustine.